Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Moingeon

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Mucosal Immunology|October 13, 2016
The regulatory dendritic cell marker C1q is a potent inhibitor of allergic inflammationL Mascarell, S Airouche, N Berjont, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|November 28, 2012
Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapyM Bonvalet, H Moussu, E Wambre, et al.
Allergy|January 26, 2017
Novel approaches and perspectives in allergen immunotherapyH J Hoffmann, E Valovirta, O Pfaar, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|November 23, 2013
Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapyV Baron-Bodo, S Horiot, A Lautrette, et al.
Allergy|December 17, 2013
Respiratory allergen from house dust mite is present in human milk and primes for allergic sensitization in a mouse model of asthmaP Macchiaverni, A Rekima, M Turfkruyer, et al.
Allergy|September 3, 2011
Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacyL Van Overtvelt, V Baron-Bodo, S Horiot, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|November 26, 2010
Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4(+) T cell responsesE Wambre, M Bonvalet, V B Bodo, et al.
Allergy|January 30, 2015
Characterization of oral immune cells in birch pollen-allergic patients: impact of the oral allergy syndrome and sublingual allergen immunotherapy on antigen-presenting cellsL Mascarell, S Rak, M Worm, et al.
Pharmeuropa Bio & Scientific Notes|January 19, 2013
Establishment of recombinant major allergens Bet v 1 and Phl p 5a as Ph. Eur. reference standards and validation of ELISA methods for their measurement. Results from feasibility studiesS Vieths, D Barber, M Chapman, et al.
Allergy|April 8, 2015
Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patientsE Nony, J Bouley, M Le Mignon, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Mucosal Immunology|October 13, 2016
The regulatory dendritic cell marker C1q is a potent inhibitor of allergic inflammationL Mascarell, S Airouche, N Berjont, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|November 28, 2012
Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapyM Bonvalet, H Moussu, E Wambre, et al.
Allergy|January 26, 2017
Novel approaches and perspectives in allergen immunotherapyH J Hoffmann, E Valovirta, O Pfaar, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|November 23, 2013
Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapyV Baron-Bodo, S Horiot, A Lautrette, et al.
Allergy|December 17, 2013
Respiratory allergen from house dust mite is present in human milk and primes for allergic sensitization in a mouse model of asthmaP Macchiaverni, A Rekima, M Turfkruyer, et al.
Allergy|September 3, 2011
Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacyL Van Overtvelt, V Baron-Bodo, S Horiot, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|November 26, 2010
Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4(+) T cell responsesE Wambre, M Bonvalet, V B Bodo, et al.
Allergy|January 30, 2015
Characterization of oral immune cells in birch pollen-allergic patients: impact of the oral allergy syndrome and sublingual allergen immunotherapy on antigen-presenting cellsL Mascarell, S Rak, M Worm, et al.
Pharmeuropa Bio & Scientific Notes|January 19, 2013
Establishment of recombinant major allergens Bet v 1 and Phl p 5a as Ph. Eur. reference standards and validation of ELISA methods for their measurement. Results from feasibility studiesS Vieths, D Barber, M Chapman, et al.
Allergy|April 8, 2015
Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patientsE Nony, J Bouley, M Le Mignon, et al.
Pageof 9